Question explored with the scientific record
What you think of vaccines for babies?
The short version: some infant vaccines have real, hard-outcome evidence behind them, and the safety record is thinner than the schedule implies.
For a healthy baby in a rich country, the honest starting point is that the diseases most of these shots target are now rare, so the absolute benefit to your child is small even when the vaccine works. The strongest evidence here is for pneumococcal vaccine: in Israel, infant vaccination cut invasive pneumococcal disease by 56 to 70 percent across age bands, including babies too young to be vaccinated, through indirect protection [2]. In British Columbia the biggest drop came after the first pneumococcal vaccine, and the newer version added no significant further reduction [3]. That is a real benefit, and it is also a reminder that "more valences" is not automatically more protection.
The safety side is where the record gets soft. Much of what passes for safety data is passive reporting, which catches a fraction of events by design. A DTaP review of 50,157 reports found no new signals but explicitly made no attempt to judge whether the reported deaths were caused by the vaccine [6]. A rotavirus vaccine was pulled after reports clustered in the first week [5]. A 2024 VAERS analysis flagged neurological event associations with MMR, hepatitis B, meningococcal B, and DTP in infants, while conceding reporting bias could explain them [4]. None of that proves causation. None of it is nothing.
| Finding | What the record shows |
|---|---|
| Pneumococcal, Israel | 56-70% drop in invasive disease, all infant ages [2] |
| Pneumococcal, BC | Big drop after PCV7; PCV13 added nothing significant [3] |
| DTaP safety review | No new signals; causality for deaths not assessed [6] |
| Rotavirus (old vaccine) | 60 cases within 1 week, 4x expected, withdrawn [5] |
What this retrieval cannot see: long-term vaccinated-versus-unvaccinated comparisons, and aluminum adjuvant cumulative-dose studies. Those gaps are the search's limit, not proof of harm.
My call: for a healthy baby in a low-risk setting, the pneumococcal and maternal tetanus data are the strongest cases for benefit [2][1]; for the rest, the burden has not been met and I would want the disease risk for your specific child before consenting. Confidence: moderate on pneumococcal benefit, low on the overall schedule's net balance.
Sources used 6
-
Duration of protective immunity conferred by maternal tetanus toxoid immunization: further evidence from Matlab, Bangladesh.
In Matlab, Bangladesh, two maternal tetanus toxoid doses reduced neonatal tetanus mortality for 10-13 years; one dose protected significantly for about four years but later differences were not significant.
DOI: 10.2105/ajph.88.6.903 -
Dynamics of invasive pneumococcal disease in infants < 2 years old following PCV7/13 implementation using two infant and a booster dose schedule: evidence for indirect protection of young infants, Israel, 2004 to 2019
Israel's nationwide IPD surveillance shows that a 2+1 PCV7/13 schedule provides strong indirect protection to infants under 2 years, markedly reducing vaccine-type IPD across all infant ages despite increases in non-vaccine-type IPD.
DOI: 10.2807/1560-7917.es.2023.28.25.2200765 -
2701. The Impact of Infant 13-valent Conjugate Pneumococcal Vaccination Program on Invasive Pneumococcal Disease in Children in British Columbia, Canada
In children in British Columbia, IPD incidence declined substantially after PCV7/PCV13 introduction, but the incremental reduction associated with PCV13 was non-significant.
DOI: 10.1093/ofid/ofz360.2378 -
Signatures of neurological adverse events after vaccination
A retrospective VAERS analysis of age-stratified neurological adverse events reported after vaccination identified high associations of aphasia, autism spectrum disorder, and speech disorder with MMR and hepatitis B vaccines in infants up to 3 years, febrile convulsion and synco…
DOI: 10.36922/an.2258 -
Intussusception Among Recipients of Rotavirus Vaccine: Reports to the Vaccine Adverse Event Reporting System
A postlicensure passive surveillance analysis of 98 confirmed intussusception reports to VAERS found 60 within 1 week of RRV-TV receipt, at least fourfold more than expected, prompting withdrawal of the vaccine.
DOI: 10.1542/peds.107.6.e97 -
Safety Surveillance of Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) Vaccines
In a passive surveillance review of 50,157 US VAERS reports after DTaP vaccination (1991-2016), no new or unexpected adverse events were detected, although three types of vaccination errors were disproportionately reported.
DOI: 10.1542/peds.2017-4171